What is the NOAEL for Imidazolidinyl urea?
Imidazolidinyl urea has 97 NOAEL studies in the database. The lowest reported value is 0.9 % via Dermal. Source: NTP ICE skin sensitization.
Also known as: EINECS 254-372-6, UNII-M629807ATL, N,N''-methylenebis(N'-(3-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl)urea), methanebis(N,N'-(5-ureido-2,4-diketotetrahydroimidazole)-N,N-dimethylol)
CAS 39236-46-9
Imidazolidinyl urea (CAS 39236-46-9) is a chemical substance. Key regulatory status: REACH registered, 14 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, ECHA REACH.
CAS, identifiers, formula, and alternate names for the matched substance record.
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| Europe; Personal care - body hygiene - hand soap | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care - specialized bath products - bath salts | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care - general moisturizing - hand/body lotion | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
| children; Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
| Europe; Personal care - deodorant | Danish Environmental Protection Agency | Danish EPA |
| Personal care - general moisturizing | P&G | Proctor & Gamble |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Europe; Personal care | European Commission | CosIng |
| active_ingredient; Europe; Pesticides | Commission of the European Communities | CPCat |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 57.24 | uM | AC50 | - | - | NTP ICE endocrine |
| 58.85 | uM | ACC | - | - | NTP ICE endocrine |
| 39.3 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| 7.921 | ug/mL | CD86, EC120 | Dermal | - | NTP ICE skin sensitization |
| 11.2 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 11.43 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 42.3 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 28.46 | ug/mL | CV70 | Dermal | - | NTP ICE skin sensitization |
| 40.1 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 55 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 7.5 | % | Concentration, 5% incidence of positive responses | Dermal | Human | NTP ICE skin sensitization |
| 1 | % | Concentration, one positive response | Dermal | Human | NTP ICE skin sensitization |
| =24.5 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB GESTIS DNEL |
| 3.8 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 40.9 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 47.8 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 48 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 52.3 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 55.9 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 58.5 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 59 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 0.9 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 1.3 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 14.6 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 15.9 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 17.1 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 20.6 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 21.1 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 25.7 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 2.4 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 26.8 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 27.75 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 31.85 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 33 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 38.5 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 39.8 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 42.1 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 18.58 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 29.26 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 29.9 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 31.1 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 31.22 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 31.3 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 31.44 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 32.2 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 32.38 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 32.7 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 32.97 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 33.26 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 33.32 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
Showing 50 of 97 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | N,N''-methylenebis[N'-[3-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]urea] | 254-372-6 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
Imidazolidinyl urea has 97 NOAEL studies in the database. The lowest reported value is 0.9 % via Dermal. Source: NTP ICE skin sensitization.
Imidazolidinyl urea appears on 10 regulatory/inventory lists including Europe; Personal care - body hygiene - hand soap, children; Europe; Personal care, children; Europe; Personal care - specialized bath products - bath salts, and 7 more. Source: EPA CPDat.
Yes, Imidazolidinyl urea is also indexed as a cosmetic ingredient under the name Imidazolidinyl Urea. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
Imidazolidinyl urea also appears in cosmetics, pharmaceutical databases.